Olema Pharmaceuticals, Inc. (NASDAQ:OLMA – Get Rating) – Stock analysts at Jefferies Financial Group decreased their Q2 2022 EPS estimates for shares of Olema Pharmaceuticals in a report released on Monday, May 9th. Jefferies Financial Group analyst M. Yee now anticipates that the company will earn ($0.68) per share for the quarter, down from their prior forecast of ($0.65). Jefferies Financial Group also issued estimates for Olema Pharmaceuticals’ Q3 2022 earnings at ($0.73) EPS, Q4 2022 earnings at ($0.81) EPS, FY2022 earnings at ($2.81) EPS and FY2023 earnings at ($3.65) EPS.
A number of other brokerages have also recently weighed in on OLMA. Zacks Investment Research cut shares of Olema Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday. HC Wainwright began coverage on shares of Olema Pharmaceuticals in a research report on Monday, February 28th. They issued a “neutral” rating on the stock.
Olema Pharmaceuticals (NASDAQ:OLMA – Get Rating) last announced its quarterly earnings data on Monday, May 9th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.01).
Several hedge funds have recently made changes to their positions in the stock. Renaissance Technologies LLC bought a new stake in Olema Pharmaceuticals in the 1st quarter valued at about $1,054,000. BlackRock Inc. increased its position in Olema Pharmaceuticals by 11.1% during the 1st quarter. BlackRock Inc. now owns 2,552,949 shares of the company’s stock worth $10,874,000 after purchasing an additional 254,785 shares in the last quarter. Acadian Asset Management LLC increased its position in Olema Pharmaceuticals by 14.4% during the 1st quarter. Acadian Asset Management LLC now owns 115,076 shares of the company’s stock worth $489,000 after purchasing an additional 14,454 shares in the last quarter. Running Point Capital Advisors LLC acquired a new position in Olema Pharmaceuticals during the 1st quarter worth approximately $43,000. Finally, JPMorgan Chase & Co. increased its position in Olema Pharmaceuticals by 20.6% in the 1st quarter. JPMorgan Chase & Co. now owns 28,800 shares of the company’s stock valued at $122,000 after acquiring an additional 4,928 shares during the period.
Olema Pharmaceuticals Company Profile (Get Rating)
Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer.
- Get a free copy of the StockNews.com research report on Olema Pharmaceuticals (OLMA)
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
- Carvana Insiders Buy Shares But Maybe You Shouldn’t
Receive News & Ratings for Olema Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Olema Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.